Maintenance treatment of gastroesophageal reflux disease: An evaluation of continuous and on-demand therapy with rabeprazole 20 mg

Canadian Journal of Gastroenterology

Volumn 21, Issue 12, 2007, Pages 820-826

  Morgan, David G ^a   O'Mahony, Michael F J ^b   O'Mahony, William F ^c   Roy, Jean ^d   Camacho, Fernando ^e   Dinniwell, Julie ^f   Horbay, G L A ^f   Husein Bhabha, Farah A ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b London Road Diagnostic Clinic ^*  (Canada)

^c Medical Research Centre   (Canada)

^d Clinique Medicale Les Saules   (Canada)

^e DAMOS Inc   (Canada)

^f Janssen Ortho Inc   (Canada)

Author keywords

Continuous therapy; GERD; Heartbum; Maintenance; On demand therapy; Rabeprazole

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE;

ABDOMINAL CRAMP; ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOATING; BRONCHITIS; CANADA; CLINICAL TRIAL; COMMON COLD; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIGASTRIC DISCOMFORT; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HUMAN; INFLUENZA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MULTICENTER STUDY; OPEN STUDY; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; SKIN IRRITATION; SMOKING; STOMACH PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 39149145452     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/203201     Document Type: Article

References (18)

1. Zacny J, Zamakhshary M, Sketris I, Veldhuyzen van Zanten S. Systematic review: The efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 2005;21:1299-312.
2. Remak E, Brown RE, Yuen C, Robinson A. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK. Curr Med Res Opin 2005;21:1506-17.
3. Armstrong D, Marshall JK, Chiba N, et al, for the Canadian Association of Gastroenterology GERD Consensus Group. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol 2005;19:15-35.
4. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001;15:347-54.
5. Dent J, Talley NJ. Overview: Initial and long-term management of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;17(Suppl 1):53-7. Review
6. Howden CW, Henning JM, Huang B, Lukasik N, Freston JW. Management of heartburn in a large, randomized, community-based study: Comparison of four therapeutic strategies. Am J Gastroenterol 2001;96:1704-10. (Erratum in Am J Gastroenterol 2001;96:2809).
7. Bytzer P, Blum A, De Herdt D, Dubois D, for The Trial Investigators. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2004;20:181-8.
8. Ponce J, Arguello L, BasTida G, Ponce M, Ortiz V, Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: Effectiveness, health-related quality of life, and patient satisfaction. Dig Dis Sci 2004;49:931-6.
9. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999;13:907-14.
10. Junghard O, Carlsson R, Lind T. Sufficient control of heartburn in endoscopy-negative gastro-oesophageal reflux disease trials. Scand J of Gastroenterol 2003;33:1197-9.
11. ICH Secretariat. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline for Good Clinical Practice, 1997.
12. Veldhuyzen van Zanten SJO, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ 2000;162(12 Suppl):S3-23.
13. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998;33:1023-9
14. Rothman M, Farup C, Stewart W, Helbers L, Zeldis J. Symptoms associated with gastroesophageal reflux disease: Development of a questionnaire for use in clinical trials. Dig Dis Sci 2001;46:1540-9.
15. De la Loge C, Rentz A, Dubois D, Jones B, Peeters K, Marquis P. Development and initial psychometric validation of the patient assessment of upper gastrointestinal disorders - quality of life instrument (PAGI-QOL) in GI patients. Value Health 2000;3:358.
16. Sjöstedt S, Befrits R, Sylvan A, et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005;22:183-91.
17. Kao A, Sheu B, Sheu M, et al. On-demand therapy for Los Angeles grade A and B reflux esophagitis: Esomeprazole versus omeprazole. J Formos Med Assoc 2003;9:607-12.
18. Lee TJ, Fennerty MB, Howden CW. Systematic review: Is there excessive use of proton pump inhibitors in gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2004;20:1241-51.